Wondering if Regeneron Pharmaceuticals at around US$764.93 a share still offers value, or if most of the upside is already ...

Fintel reports that on March 6, 2026, Barclays initiated coverage of Regeneron Pharmaceuticals (NasdaqGS:REGN) with a Overweight recommendation. Analyst Price Forecast Suggests 15.10% Upside As of ...

Biotech stocks may offer your portfolio an element of growth, and that's because these companies are sharply focused on ...

Analysts have set 12-month price targets for Regeneron Pharmaceuticals, revealing an average target of $838.07, a high estimate of $975.00, and a low estimate of $745.00. This upward trend is evident, ...

Regeneron and Sanofi win CHMP backing to expand Dupixent use to young CSU patients, with EU and U.S. decisions poised to unlock a new growth avenue.

Here is why we believe Regeneron Pharmaceuticals (REGN) stock is worthy of consideration as a value investment. It is presently trading nearly 38% lower than its one-year peak, and is also being ...

Longleaf Partners, managed by Southeastern Asset Management, released its fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. The Fund returned 3.35% in the quarter, ...

Regeneron Pharmaceuticals stock increased by 19% over the past month driven by strong third-quarter earnings and robust sales of its flagship drugs, Dupixent (for eczema and other inflammatory ...

Tyler Van Buren here, senior biotech analyst at TD Cowen. Thank you very much for joining TD Cowen's 46th Annual Healthcare Conference. For next session or first session of the day, actually, very ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the top gene therapy stocks to buy according to hedge funds. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced on February 24 that the U.S ...